CUE Insider Trading Activity and SEC Form 4 Filings
CUE insider trading summary
Over the past 12 months, insiders at Cue Biopharma, Inc. (CUE) reported 15 sales worth $2.4M by 3 insiders and 5 open-market purchases worth $100K by 1 insider on SEC Form 4. Net insider selling was $2.3M.
Latest CUE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 12, 2026 | Shao-Lee Lin | Chief Executive Officer | Sell | $30K (1,087 @ $28.05) |
| Oct 12, 2026 | Shao-Lee Lin | Chief Executive Officer | Sell | $275K (10,000 @ $27.50) |
| Oct 12, 2026 | Michael Vincent Meluzio | VP, Prin. Accounting Officer | Sell | $32K (1,144 @ $28.05) |
| Oct 12, 2026 | Sumita Ray | Chief Legal Compliance Officer | Sell | $52K (1,844 @ $28.05) |
| Aug 13, 2026 | Sumita Ray | Chief Legal Compliance Officer | Sell | $125 (4 @ $31.13) |
| Aug 13, 2026 | Sumita Ray | Chief Legal Compliance Officer | Sell | $196K (6,442 @ $30.35) |
| Aug 13, 2026 | Shao-Lee Lin | Chief Executive Officer | Sell | $308K (10,460 @ $29.48) |
| Aug 13, 2026 | Michael Vincent Meluzio | VP, Prin. Accounting Officer | Sell | $45K (1,519 @ $29.37) |
| Aug 13, 2026 | Sumita Ray | Chief Legal Compliance Officer | Sell | $70K (2,383 @ $29.37) |
| Aug 13, 2026 | Michael Vincent Meluzio | VP, Prin. Accounting Officer | Sell | $125K (4,106 @ $30.35) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.